NeoGenomics, Inc. (NASDAQ:NEO) Holdings Lowered by BNP Paribas Financial Markets

BNP Paribas Financial Markets trimmed its stake in NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 49.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 36,984 shares of the medical research company's stock after selling 35,979 shares during the quarter. BNP Paribas Financial Markets' holdings in NeoGenomics were worth $609,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. SBI Securities Co. Ltd. acquired a new stake in NeoGenomics during the fourth quarter worth about $26,000. Sterling Capital Management LLC grew its holdings in shares of NeoGenomics by 788.7% during the 4th quarter. Sterling Capital Management LLC now owns 3,706 shares of the medical research company's stock worth $61,000 after purchasing an additional 3,289 shares during the period. Smartleaf Asset Management LLC increased its position in NeoGenomics by 203.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 4,156 shares of the medical research company's stock worth $70,000 after purchasing an additional 2,787 shares in the last quarter. Blue Trust Inc. raised its holdings in NeoGenomics by 33.2% in the fourth quarter. Blue Trust Inc. now owns 4,421 shares of the medical research company's stock valued at $73,000 after buying an additional 1,103 shares during the period. Finally, KBC Group NV raised its holdings in NeoGenomics by 44.7% in the fourth quarter. KBC Group NV now owns 6,557 shares of the medical research company's stock valued at $108,000 after buying an additional 2,027 shares during the period. Institutional investors and hedge funds own 98.50% of the company's stock.

Insider Transactions at NeoGenomics

In other news, Director David Brian Perez purchased 10,000 shares of the stock in a transaction dated Monday, May 5th. The stock was acquired at an average price of $7.63 per share, for a total transaction of $76,300.00. Following the completion of the transaction, the director now owns 10,000 shares of the company's stock, valued at approximately $76,300. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Jeffrey Scott Sherman acquired 20,000 shares of the company's stock in a transaction that occurred on Friday, May 2nd. The stock was purchased at an average cost of $7.51 per share, for a total transaction of $150,200.00. Following the acquisition, the chief financial officer now owns 158,494 shares in the company, valued at approximately $1,190,289.94. This trade represents a 14.44% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders have purchased 70,600 shares of company stock valued at $550,438. Insiders own 2.40% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on NEO shares. Morgan Stanley dropped their price objective on shares of NeoGenomics from $17.00 to $10.00 and set an "equal weight" rating for the company in a research report on Thursday, May 1st. The Goldman Sachs Group decreased their target price on NeoGenomics from $15.00 to $10.00 and set a "buy" rating for the company in a research report on Wednesday, April 30th. Piper Sandler set a $12.00 target price on NeoGenomics and gave the company an "overweight" rating in a report on Tuesday, May 6th. Leerink Partnrs cut NeoGenomics from a "strong-buy" rating to a "hold" rating in a report on Wednesday, April 30th. Finally, Guggenheim assumed coverage on shares of NeoGenomics in a research report on Thursday, May 15th. They issued a "neutral" rating for the company. Seven investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, NeoGenomics has a consensus rating of "Hold" and an average price target of $13.83.

NeoGenomics Stock Down 0.7%

Shares of NeoGenomics stock traded down $0.05 on Thursday, hitting $7.37. 866,075 shares of the company's stock traded hands, compared to its average volume of 1,154,726. NeoGenomics, Inc. has a 52-week low of $6.08 and a 52-week high of $19.12. The company has a quick ratio of 1.91, a current ratio of 1.98 and a debt-to-equity ratio of 0.38. The stock has a market cap of $948.48 million, a P/E ratio of -11.89 and a beta of 1.60. The firm's 50-day moving average is $8.59 and its 200 day moving average is $12.45.

NeoGenomics (NASDAQ:NEO - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The medical research company reported ($0.08) EPS for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.06). The company had revenue of $168.04 million for the quarter, compared to the consensus estimate of $171.38 million. NeoGenomics had a negative net margin of 11.92% and a negative return on equity of 2.10%. The company's revenue was up 7.6% compared to the same quarter last year. During the same quarter last year, the company earned ($0.02) earnings per share. Equities analysts anticipate that NeoGenomics, Inc. will post -0.2 earnings per share for the current year.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.